Ozempic® or Wegovy®? Mounjaro® or Zepbound®? The naming situation is genuinely confusing. Some of these are the same drug at different doses, and some are entirely different drugs. Let’s clear it up once and for all.
The Two Drug Families
All of these medications fall under the GLP-1 umbrella, but there are two distinct drugs involved:
Semaglutide is made by Novo Nordisk. This is the active ingredient in both Ozempic® and Wegovy®.
Tirzepatide is made by Eli Lilly. This is the active ingredient in both Mounjaro® and Zepbound®.
Ozempic® vs. Wegovy®: Same Drug, Different Purpose and Dose
Ozempic® and Wegovy® both contain semaglutide, but they’re approved for different indications and come in different dose ranges.
Ozempic® is approved for type 2 diabetes. It comes in doses up to 2 mg per week and is focused on blood sugar control, though weight loss is a well-documented side effect that many patients experience. As of January 2025, Ozempic® also carries FDA approval for cardiovascular and kidney disease risk reduction in certain T2D patients.
Wegovy® is approved for chronic weight management. It tops out at 2.4 mg per week, a higher dose than Ozempic®, and was specifically studied and approved for weight loss in people with obesity or who are overweight with a related health condition. In 2024, Wegovy® also received FDA approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have both established heart disease and obesity or are overweight.
In practice, some doctors prescribe Ozempic® off-label for weight loss, particularly when Wegovy® is unavailable or not covered by insurance. Clinically, the drugs work the same way. The main difference is the approved dose and indication.
Mounjaro® vs. Zepbound®: Same Story, Different Drug
Mounjaro® is tirzepatide approved for type 2 diabetes. Zepbound® is tirzepatide approved for weight management, and as of late 2024, it’s also the first and only prescription medication approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Same relationship as Ozempic®/Wegovy®, just with a newer, different drug. Both are available in maintenance doses of 5, 10, or 15 mg per week.
What Makes Tirzepatide Different From Semaglutide
Tirzepatide is sometimes called a “dual agonist” because it activates two receptors, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in insulin release and fat metabolism. By hitting both receptors, tirzepatide appears to have a more powerful effect on weight loss than semaglutide alone.
Clinical trials comparing the two have generally shown greater average weight loss with tirzepatide, with some participants losing 20–22% of body weight at the highest doses, compared to roughly 15% with semaglutide. That said, individual responses vary a lot, and some people do better on one than the other.
Which One Is Right for You?
That’s a conversation to have with your doctor, and it’ll depend on your specific health conditions, insurance coverage, cost, and how you tolerate each medication. A few general considerations:
If you have type 2 diabetes, either drug can help with blood sugar and weight
If insurance coverage is your main concern, what’s covered varies significantly by plan and situation
If you’ve tried semaglutide without adequate results, tirzepatide may be worth discussing as a next step
Both require weekly injections (though oral semaglutide is now available for both diabetes and weight management)
Both medications share a similar side effect profile. Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, are the most commonly reported, and they tend to be most pronounced during the dose-escalation phase. Both also carry a boxed warning regarding the risk of thyroid C-cell tumors. Your doctor can walk you through the full risk profile based on your health history.
Sorting It Out
Ozempic® is semaglutide for diabetes. Wegovy® is semaglutide for weight loss. Mounjaro® is tirzepatide for diabetes. Zepbound® is tirzepatide for weight loss. And tirzepatide tends to produce somewhat greater weight loss on average, though individual results vary. Now you can confidently navigate that conversation with your doctor.
The FDA-approved GLP-1 receptor agonist medications discussed in this article are prescription medications for specific indications: semaglutide (Ozempic®) for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and cardiovascular disease; semaglutide (Wegovy®) for chronic weight management; tirzepatide (Mounjaro®) for type 2 diabetes; and tirzepatide (Zepbound®) for chronic weight management. This article is for educational and informational purposes only and does not constitute medical advice. Individual results may vary. Consult your healthcare provider to determine if GLP-1 therapy is appropriate for your individual health situation and to discuss potential risks, side effects, and contraindications.
Leave a Comment
Your email address will not be published. Required fields are marked *